Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1B | P68106 | 4/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.51 |
| ▸ | PPIA | P62937 | 15/20 | 0.49 |
| ▸ | PPIB | P23284 | 10/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.48 |
| ▸ | ABCC2 | Q92887 | 2/20 | 0.48 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976362 | 0.89 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9976370 | 0.88 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9976371 | 0.86 | ABCB1 (0.54) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9976364 | 0.86 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9976363 | 0.86 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9976354 | 0.86 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9976357 | 0.85 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9976358 | 0.84 | FKBP1B (0.45) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976368 | 0.84 | FKBP1B (0.44) | FKBP1BABCB1PPIAPPIBABCB11 | |
| SCHEMBL9880088 | 0.81 | PPIA (0.57) | PPIAPPIBCYP3A4CYP2C9PPIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267726-A1 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS | UCL BUSINESS PLC (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20160002299-A1 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS | UCL BUSINESS PLC (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002299-A1 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS | C1R, HAVCR2, CCR3 | FKBP1B 20/4885ABCB1 533/4885PPIA 228/4885 |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | FKBP1B 138/4885ABCB1 70/4885PPIA 812/4885 |
| US-20170267726-A1 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS | C1R, HAVCR2, CCR1 | FKBP1B 31/4885ABCB1 488/4885PPIA 229/4885 |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | FKBP1B 141/4885ABCB1 68/4885PPIA 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.